Subcutaneous administration of Herceptin Hylecta resulted in non-inferior levels of trastuzumab in the blood (pharmacokinetics) and non-inferior clinical efficacy (pathological complete response ...

13, 2018 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) announced today that Health Canada has approved a subcutaneous formulation of HERCEPTIN for the treatment of early and metastatic stage ...

Back to Healio Subcutaneous trastuzumab was observed to have a safety profile and efficacy similar to standard IV administration, offering a viable treatment alternative, according to study ...

The subcutaneous regimen also reduced pharmacy burdens. Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I HER2-positive breast cancer ...

Subcutaneous administration of trastuzumab/pertuzumab could save breast cancer patients and healthcare providers substantial amounts of time compared with intravenous ...

Sixty-three patients were enrolled in the phase 2 IMMUN-HER study (NCT03144947) evaluating SC (n = 32) vs IV (n = 31) trastuzumab administration. In the IV trastuzumab arm, 20 of 31 patients (64.5 ...

Subcutaneous delivery has been used for some time, including for well-known therapies such as trastuzumab (Herceptin), which is used in HER2-positive breast cancer, and bortezomib (Velcade), and ...

Roche has had time to defend Herceptin against biosimilars, however. A patent-protected subcutaneous formulation of the drug was launched some years ago, and now represents 50% or more of the market.

Herceptin SC is given as a subcutaneous injection (under the skin) over 2 to 5 minutes every three weeks. More instructions can be found in Section 4. How do I use Herceptin SC? in the full CMI.

We've already seen applications for approval of a subcutaneous form of atezolizumab ... of drugs like Rituxan [rituximab] and drugs like Herceptin [trastuzumab]. We know that this is a formulation ...

to develop and commercialize a subcutaneous version of ENHERTU ® (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate (ADC) that has been jointly developed and ...

2 Slamon D et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N Engl J Med 2011; 365:1273-83. 3 Pivot, Semiglazov et al. Subcutaneous injection of trastuzumab – analysis of ...